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ABSTRACT
Hepatoblastomas are uncommon embryonal liver tumors accounting for 
approximately 80% of childhood hepatic cancer. We hypothesized that epigenetic 
changes, including DNA methylation, could be relevant to hepatoblastoma onset. The 
methylomes of eight matched hepatoblastomas and non-tumoral liver tissues were 
characterized, and data were validated in an independent group (11 hepatoblastomas). 
In comparison to differentiated livers, hepatoblastomas exhibited a widespread and 
non-stochastic pattern of global low-level hypomethylation. The analysis revealed 
1,359 differentially methylated CpG sites (DMSs) between hepatoblastomas and 
control livers, which are associated with 765 genes. Hypomethylation was detected in 
hepatoblastomas for ~58% of the DMSs with enrichment at intergenic sites, and most 
of the hypermethylated CpGs were located in CpG islands. Functional analyses revealed 
enrichment in signaling pathways involved in metabolism, negative regulation of cell 
differentiation, liver development, cancer, and Wnt signaling pathway. Strikingly, an 
important overlap was observed between the 1,359 DMSs and the CpG sites reported 
to exhibit methylation changes through liver development (p<0.0001), with similar 
patterns of methylation in both hepatoblastomas and fetal livers compared to adult 
livers. Overall, our results suggest an arrest at early stages of liver cell differentiation, 
in line with the hypothesis that hepatoblastoma ontogeny involves the disruption of 
liver development. This genome-wide methylation dysfunction, taken together with 
a relatively small number of driver genetic mutations reported for both adult and 
pediatric liver cancers, shed light on the relevance of epigenetic mechanisms for 
hepatic tumorigenesis.
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INTRODUCTION
DNA methylation in mammals plays a key role 
in embryonic and differentiation processes through the 
modulation of chromatin compaction states leading to 
domains of variation in transcriptional activities [1]. The 
Developmental Origins of Health and Disease (DOHaD) 
hypothesis postulates that environmental factors acting in 
utero, together with genetic factors, may greatly influence 
disease susceptibility and outcomes in both infancy and 
adulthood [2, 3], particularly modulating alterations in 
DNA methylation in pediatric pathological conditions [4].
A specific class of pediatric cancers – the embryonal 
tumors – is defined based on embryonic features of the 
tumors and their very early age of onset. A relatively small 
number of genetic mutations have been reported in pediatric 
tumors compared to adult solid tumors [5, 6], and this paucity 
of mutations may be partially correlated with the early age of 
onset [5]. Another possible explanation is that mechanisms 
other than DNA mutation may disrupt cell differentiation 
processes during development, a model that has been 
proposed for embryonal tumors [7]. Hepatoblastomas are 
embryonal tumors of the liver and are the most common 
hepatic tumors of early childhood, with an incidence in the 
United States estimated to be between 5.2 and 10.5 cases 
per million children <1 and 1-4 years old, respectively [8]. 
In Brazil, an age-adjusted incidence rate of 2.8 per million 
children less than 15 years of age has been reported [9]. Due 
to their rarity, knowledge regarding genetic predisposing 
factors for hepatoblastoma is limited. Indeed, few genetic 
alterations have been found in both cytogenetic and point 
mutation studies of hepatoblastomas. The identified genetic 
alterations are primarily linked to the Wnt signaling 
pathway, with a relatively high frequency of CTNNB1 
activating mutations [10, 11]; its role was demonstrated 
after insertion of CTNNB1 mutations in precursor liver cells, 
resulting in high incidence of hepatocellular carcinomas and 
hepatoblastomas in mice [12].
A less studied pathway that could partially explain 
both developmental disruption  and cancer development 
is the occurrence of epigenetic changes [3, 4]. DNA 
methylation is a stable modification involved in many 
biological processes, including tissue differentiation, 
embryogenesis, and disease development [13]. In general, 
whereas normal cells usually have unmethylated gene 
promoters and CpG islands, and heavily methylated 
repetitive sequences, the opposite pattern is found in 
tumor cells. Anomalous DNA methylation represents an 
important mechanism driving tumor development and 
progression [14]. Although the roles of DNA methylation 
in oncogenesis have not yet been fully elucidated, 
promoter hypermethylation has been shown to be 
associated with inappropriate transcriptional repression of 
tumor suppressor genes, and hypomethylation of repetitive 
sequences may result in activation of retro-transposon 
elements and genomic instability [15, 16].
To date, most of studies investigating DNA 
methylation in hepatoblastomas have focused on specific 
genes or genomic regions. Site-specific hypermethylation of 
selected imprinted regions were reported in hepatoblastomas 
in comparison to normal liver counterparts, suggesting that 
aberrant DNA methylation is associated to hepatoblastoma 
formation [17]. Hypermethylation of the promoter regions 
of RASSF1A [18–20], CASP8 [18], SOCS1 [21–23], 
APC, CDH1, MT1G [23], HHIP [10], CDKN2A [24], 
and IGF2 [18, 23] were also reported. Additionally, 
hypomethylation of IGFBP3 [25] has been described in 
a subgroup of tumors. To date, only two genome-wide 
methylation studies in hepatoblastoma samples have been 
published. In one of them, the comparison of three matched 
tumor-normal samples revealed genes exhibiting aberrant 
methylation that were involved with cell adhesion, blood 
coagulation and nervous system development, in addition 
to low methylation level near the transcriptional start site 
of the alpha fetoprotein gene [26]. The second one reported 
the investigation of hepatoblastomas from two patients, 
and revealed four genes, GPR180, MST1R, OCIAD2 and 
PARP6, with methylation status that could be associated 
with clinical parameters, such as age at diagnosis and poor 
outcome [27].
In the present study, we carried out an extensive 
methylation analysis across the entire genome using 
two independent cohorts of hepatoblastomas (8 tumors 
paired with their adjacent normal liver tissues from the 
same patients, and 11 hepatoblastomas and 3 normal 
liver tissues from different patients). We examined the 
DNA methylation status of >450,000 CpG sites, as well 
as LINE-1 sequences throughout the entire genome. The 
methylation levels of hepatoblastomas were compared on 
a locus by locus basis with those found in non-tumoral 
liver samples. Furthermore, we interrogated the extent 
of the overlap between the differentially methylated sites 
(DMSs) here detected in hepatoblastomas and the CpG 
sites reported to exhibit methylation changes through liver 
development.
RESULTS
A trend toward global DNA hypomethylation 
was detected in hepatoblastomas
We analyzed 19 hepatoblastomas using a discovery 
group (Hepatoblastoma set #1) and a validation group 
(Hepatoblastoma set #2). This strategy was used to lessen 
the number of false negatives because we studied a small 
sample size. The clinical features of the patients with 
hepatoblastomas are summarized in Table 1.
Prior to the differential methylation analyses, 
several parameters were considered to infer surrogate 
variables that could impact the comparison of interest. 
These analyses did not detect any association with 
the investigated co-variables (age at diagnosis, tumor 
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Table 1: Clinical characterization of the 19 patients with hepatoblastomas
ID Age at diagnosis Gender Histology* Treatment Protocol Recurrence Metastasis Overall survival
HB15 2.5 years F Embryonal PRETEXT - - 1 year
HB16# 10 months M Fetal PRETEXT III - - > 11 years
HB17 3.0 years F Fetal PRETEXT III - - > 10 years
HB18# 9 months M Embryonal PRETEXT III - - > 9 years
HB28 20.0 years M Embryonal PRETEXT IV yes - 1 year
HB30 5.5 years M
Mixed fetal 
(85%) /
embryonal (10%) 
+ small cells 
(5%)
PRETEXT IV N/A yes (lung) N/A
HB31 2.0 years M Fetal PRETEXT - - > 5 years
HB32 5 months F Embryonal PRETEXT IV - yes (lung) > 5 years
HB33# 3 months F Fetal PRETEXT III - - > 2 years
HM35# 2.2 years M Fetal PRETEXT III - - > 10 years
HB37 1.1 year F
Mixed fetal 
(5%)/embryonal 
(40%) + tumoral 
stroma (55%) 
+ non-tumoral 
stroma (10%)
PRETEXT - - > 7 years
HB38 12.0 years F
Fetal + non-
tumoral stroma 
(10%)
PRETEXT IV - - > 2 years
HB39 7.0 years M
Fetal + non-
tumoral stroma 
(30%)
PRETEXT II - - 8 months
HB40 2.0 years M Fetal PRETEXT - - > 4 years
HB41 2.0 years M
Mixed fetal/
embryonal + 
tumoral stroma 
(55%)
COG - yes (lung) > 2.5 years
HB42 13.0 years M Fetal + tumoral stroma (50%) PRETEXT - - N/A
HB43 1.5 years M
Embryonal + 
tumoral stroma 
(50%)
PRETEXT III - - > 6 years
HB44 4.5 years M
Embryonal + 
tumoral stroma 
(30%)
PRETEXT - - N/A
HB45 5 months F Fetal (90%) PRETEXT - - 8 months
Eight cases with matched hepatoblastomas and non-tumoral liver samples are labeled in bold. Abbreviations: F: Female; 
M: Male; N/A: not available. *The histology description refers to the frozen tissue sent to DNA extraction. #tumors carrying 
a CTNNB1 mutation.
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histology, alpha-fetoprotein levels, treatment protocol, 
progression and overall survival). The mean and standard 
deviation of the methylation levels (beta-values ranging 
from 0 to 1) were very similar within each of the four 
groups of comparison, Hepatoblastomas set #1 (0.49 +/-
0.37) and set #2 (0.48 +/- 0.37), and control groups of 
non-tumor differentiated liver set #1 (0.52 +/- 0.36) and 
set #2 (0.52 +/- 0.36), indicating similar levels of inter- 
and intra-group heterogeneity, i.e., among the different 
samples of hepatoblastomas and the different samples of 
differentiated livers.
The comparison between hepatoblastomas and their 
matched non-tumoral liver tissues from set #1 revealed 
1,399 differentially methylated CpG sites (adjP<0.05) – 
DMSs -, with 820 hypomethylated CpGs (551 of them 
related to 457 genes), and 579 hypermethylated CpGs 
(456 of them related to 363 genes) (Figure 1A, left). A 
validation set of 12 hepatoblastomas (Hepatoblastoma set 
#2) was used to replicate the analysis, using as a control 
group the same non-tumoral liver samples plus additional 
three samples. The set #2 comparison exhibited 61,384 
DMSs (adjP<0.05) with a large proportion of them (86.7%; 
53,222 CpGs) showing hypomethylation. There was an 
overlap of 1,359 DMSs (97% of the CpGs detected in the 
paired differential methylation analysis) between both 
analyses (Figure 1A; Supplementary Table 1) affecting 
765 genes; common DMSs were either hypermethylated or 
hypomethylated CpGs in both hepatoblastoma sets, with 
a maximum beta-value variation of 0.21, and an average 
deviation of 0.009. Unsupervised hierarchical clustering 
analysis based on the methylation levels of these common 
1,359 DMSs discriminated all control livers from 18 out 
of 19 hepatoblastoma samples (Supplementary Figure 1), 
except for tumor sample HB17. We did not obtain a clear 
discrimination of tumor subgroups based on the clinical 
characteristics of the patients, but given the small size of 
the cohort, this observation is not conclusive.
The common set of DMSs displayed a non-random 
distribution regarding different categories of genomic 
sequences being mostly hypermethylated at gene bodies 
and CpG islands, and hypomethylated at intergenic 
regions (p<0.0001; chi-square distribution test, Table 
2). Additionally, we inspected the distribution of the 
DMSs across the autosomes considering the paired and 
non-paired analyses separately, seeking to uncover a 
preferential gain or loss of methylation in a specific 
Figure 1: Characterization of the differentially methylated CpG sites (DMSs) detected in hepatoblastomas compared 
to control liver samples. A. Volcano plots of the paired (set#1, at left) and non-paired (set #2, at right) differential methylation analysis 
of hepatoblastomas in comparison to control liver tissues. The X and Y axes display, respectively, the delta-beta value (methylation 
differences between groups), and the log of the adjusted p-values for each CpG site; above the horizontal black lines, CpG sites considered 
to be differentially methylated (adjP<0.05). The green dots identify CpG sites displaying >20% methylation difference between tumor 
and control samples; the number of hypo and hypermethylated sites are indicated by the “n” values displayed, respectively, at left and 
right top of each Volcano plot. The Venn-diagram in the middle shows the overlapping DMSs that were detected both in set #1 and set 
#2 of hepatoblastomas. B. Distribution of the delta beta mean values (Y axis) of the set of 1,359 common DMSs across the autosomes 
(rectangular boxes), their corresponding standard deviations (vertical bars) and median values (horizontal bar). Paired (red) and non-paired 
(green) analyses are shown separately. Outliers are represented by dots.
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chromosome (Figure 1B). The autosomes in which the 
differences of the DMSs were positive (i.e. meaning that 
the CpG sites were more methylated in hepatoblastomas 
compared with non-tumoral livers) were chromosomes 
6, 9, 11, 20 and 22. Therefore, most of the DMSs were 
hypomethylated in the majority of the chromosomes, 
suggesting a widespread and non-randomic pattern of 
hypomethylation.
DNA methylation is considered a repressive 
epigenetic mark that characterizes most CpG sites 
within mammalian genomes. However, CpG dense 
regions, mainly CpG islands, are generally unmethylated 
in normal cells [28]. Additionally, DNA methylation 
values represent a mix of different cell types, thus, small 
methylation changes may correspond to an epigenetic drift 
of a subset of cells. Therefore, trying to identify CpG sites 
with more impact for the disease as a whole, we used an 
additional threshold of ≥20% methylation difference in 
hepatoblastomas compared to control livers. We defined 
differentially methylated regions (DMRs) based on 
sequences containing ≥3 significant CpG sites, all in the 
same direction (hypomethylation or hypermethylation) 
in the same genomic location, with at least one site 
displaying methylation differences of ≥20%. Thirty-eight 
genes were found to harbor sequences that met these 
parameters (Table 3; Supplementary Table 2 contains 
the details of the CpG sites which are related to DMRs). 
Among these 38 genes, 14 exhibited hypermethylated 
CpGs, and 23 exhibited hypomethylation, and one gene, 
TSPAN9, showed both gene body hypermethylation and 
promoter hypomethylation. One of these genes, EIF4E, 
has already been reported in liver cancer, and other 27 are 
directly related to liver function.
Differentially methylated genes in 
hepatoblastomas are involved with liver cell 
differentiation and cancer
Among the 765 genes associated with the set of 
common DMSs, there was an enrichment for Metabolic, 
Cancer, Insulin, MAPK, Hedgehog and Wnt signaling 
pathways, as well as Regulation of the actin cytoskeleton, 
Adherens junction, Glycolysis/Gluconeogenesis and 
Drug Metabolism (Supplementary Table 3). Genes with 
hypomethylated sites were related to negative regulation 
of cell differentiation (19 genes), including somatic stem 
cell maintenance; negative regulation of RNA metabolic 
processes (32 genes); and negative regulation of DNA-
Table 2: Distribution of the common set of DMSs detected in hepatoblastomas compared to control livers regarding 
their genomic location
In relation to gene
 Hypomethylated Hypermethylated p-value
1stExon 19 2% 9 2% 0.4381
3'UTR 21 3% 38 7% 0.0003
5'UTR 80 10% 48 9% 0.3977
Gene body 270 34% 250 45% <0.0001*
TSS1500 100 12% 70 13% 1,00
TSS200 46 6% 27 5% 0.5412
Intergenic region 265 33% 116 21% 0.0001*
In relation to CpG island
 Hypomethylated Hypermethylated p-value
Island 62 8% 81 15% <0.0001*
N_Shelf 31 4% 35 06% 0.0537
N_Shore 113 14% 71 13% 0.5192
S_Shelf 51 6% 36 06% 1,00
S_Shore 119 15% 55 10% 0.0065
Open sea 425 53% 280 50% 0.3206
Hypomethylated and hypermethylated CpG sites are classified in both gene and CpG island categories and shown in 
number and percentage. * Asterisks indicate either gene or CpG island category which we considered statiscally enriched 
within the group of DMSs (p<0.0001; chi-square distribution test). 
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Table 3: Description of the genes associated with 38 differentially methylated regions detected in hepatoblastomas 
compared to control liver samples
Gene Methylation change Gene category (CpG number)
CpG island 
category (CpG 
number)
*CpG island  
identification Description
ACSL1 hypermethylation
gene body  
(3 CpGs) and 5'  
UTR (1 CpG)
island (2 CpGs) 
and shores 
(2 CpGs)
chr4:185724434- 
185724647
long-chain fatty-acid-
coenzyme A ligase that plays 
a key role in lipid biosynthesis 
and fatty acid degradation
ASCL2 hypermethylation TSS1500  (12 CpGs)
island (6 CpGs) 
and S-shore 
(6 CpGs)
chr11:2290104- 
2292932
transcription factor related 
to embryonic and induced 
pluripotent stem cell 
differentiation, and early 
embryo development
CRP hypermethylation
TSS200 (1 CpG), 
TSS1500  
(1 CpG), 5'UTR 
(1 CpG)
open sea (3 CpGs) N/A
this gene belongs to the 
pentaxin family, and is 
involved in several host 
defense related functions
DEAF1 hypermethylation gene body  (3 CpGs) open sea (3 CpGs) N/A
regulator of transcription in 
embryonic development
ELFN1 hypermethylation
TSS200 (4 CpGs)  
and TSS1500  
(3 CpGs)
open sea (7 CpGs) N/A
phosphatase binding and 
protein phosphatase inhibitor 
activity
FAM50B hypermethylation TSS1500  (3 CpGs) N-shore (3 CpGs)
chr6:3849271-
3851048
imprinted gene adjacent to 
a differentially methylated 
region (DMR); paternally 
expressed in many tissues
HOXA3 hypermethylation 5' UTR (3 CpGs) island (1 CpG) and N-shore (2 CpGs)
chr7:27150030- 
27150418
homeobox gene whose 
expression is spatially and 
temporally regulated during 
embryonic development
NUAK1 hypermethylation gene body  (3 CpGs) open sea (3 CpGs) N/A
serine/threonine-protein kinase 
involved in cell adhesion, 
regulation of cell ploidy 
and senescence, and tumor 
progression
OXT hypermethylation TSS200 (4 CpGs) island (4 CpGs) chr20:3052097- 3053103
encodes a precursor protein 
that is processed to produce 
oxytocin and neurophysin I
PRRT1 hypermethylation gene body  (10 CpGs) and 3'  UTR (4 CpGs)
island (9 CpGs) 
and N-shore 
(5 CpGs)
chr6:32118101- 
32118544
proline rich transmembrane 
protein 1
RXRA hypermethylation gene body  (3 CpGs)
island (1 CpG), 
S-shore (1 CpGs) 
and open sea 
(1 CpG)
chr9:137229726- 
137229931
nuclear receptor involved in 
retinoic acid-mediated gene 
activation
SNORD46 hypermethylation gene body (3  CpGs) S-shore (3 CpGs)
chr1:45241013- 
45241900 small nucleolar RNA
THRSP hypermethylation
TSS200 (2 CpGs), 
TSS1500 (1 CpG), and 
first exon (1 CpG)
open sea (4 CpGs) N/A
gene expressed in liver and 
adipocytes, with a suggested 
role in controlling tumor lipid 
metabolism
(Continued )
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Gene Methylation change Gene category (CpG number)
CpG island 
category (CpG 
number)
*CpG island  
identification Description
ADAMTS17 hypomethylation gene body (3 CpGs) open sea (3 CpGs) N/A
disintegrin and 
metalloproteinase with 
thrombospondin motifs 
(ADAMTS family)
AGL hypomethylation gene body (3 CpGs) open sea (3 CpGs) N/A
glycogen debrancher enzyme 
which is involved in glycogen 
degradation
AHRR hypomethylation gene body (3 CpGs)
N-shore (2 CpGs) 
and open sea 
(1 CpG)
chr5:370185- 
370422
protein of the aryl 
hydrocarbon receptor (AhR) 
signaling cascade; involved in 
regulation of cell growth and 
differentiation
ASPSCR1 hypomethylation gene body (3 CpGs)
island (2 CpGs) 
and N-shore 
(1 CpG)
chr17:79952141-
79952494
a tether, which sequesters 
GLUT4 in the absence of 
insulin
BMP4 hypomethylation TSS1500 (3 CpGs) S-shore (3 CpGs) chr14:54420184-54422958
member of the bone 
morphogenetic protein (BMP) 
family of proteins, and of the 
transforming growth factor-
beta (TGF-beta) superfamily; 
may also be involved in 
human cancers
CACNA1H hypomethylation gene body (3 CpGs)
island (2 CpGs) 
and S-shore 
(1 CpG)
chr16:1208357- 
1208721
protein in the voltage-
dependent calcium channel 
complex
CACNB4 hypomethylation gene body (5 CpGs) open sea (5 CpGs) voltage-dependent calcium channel complex protein
EIF4E hypomethylation 5' UTR (4 CpGs) S-shore (4 CpGs) chr4:99849305-99850552
component of the eukaryotic 
translation initiation factor 
4F complex; acts as a proto-
oncogene
GHDC hypomethylation TSS200 (3 CpGs) open sea (3 CpGs) 17:40346266- 40346800 GH3 domain containing
GRM8 hypomethylation gene body (2 CpGs) and TSS200 (1 CpG) open sea (3 CpGs)
metabotropic glutamate 
receptor; linked to the 
inhibition of the cyclic AMP 
cascade
IKZF4 hypomethylation TSS200 (2 CpGs) and TSS1500 (1 CpG) open sea (3 CpGs) N/A
transcription factor, expressed 
in lymphocytes and implicated 
in the control of lymphoid 
development
KCNMA1 hypomethylation gene body (3 CpGs) open sea (3 CpGs) N/A
pore-forming subunit of large 
conductance, voltage and 
calcium-sensitive potassium 
channels
LGALS3BP hypomethylation TSS200 (1 CpG) and TSS1500 (2 CpGs) open sea (3 CpGs)
17:76975867-
76976452
beta-galactoside-binding 
protein implicated in 
modulating cell-cell and cell-
matrix interactions
(Continued )
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Gene Methylation change Gene category (CpG number)
CpG island 
category (CpG 
number)
*CpG island  
identification Description
MAP3K8 hypomethylation 5' UTR (6 CpGs)
S-shore (5 CpGs) 
and S-shelf (1 
CpG)
10:30725901-
30727142
oncogene that encodes 
a member of the serine/
threonine protein kinase 
family
MRGPRF hypomethylation TSS1500 (3 CpGs) S-shelf (3 CpGs) chr11:68778569-68778851
MAS related GPR family 
member F
NR2F2 hypomethylation
TSS200 (5 CpGs), 
TSS1500 (1 CpGs) and 
5' UTR (1 CpG)
S-shelf (7 CpGs) chr15:96864881-96866787
ligand inducible transcription 
factor that is involved in the 
regulation of many different 
genes
PFKP hypomethylation gene body (3 CpGs) S-shore (3 CpGs) chr10:3148406-3148625
platelet isoform of 
phosphofructokinase; 
key regulatory enzyme in 
glycolysis
SECTM1 hypomethylation gene body (1 CpG) and 3' UTR (3 CpGs)
island (3 CpGs) 
and N-shelf 
(1 CpG)
chr17:80278861-
80279563
transmembrane and secreted 
protein thought to be involved 
in hematopoietic and/or 
immune system processes
SLC16A1 hypomethylation TSS1500 (4 CpGs) S-shore (4 CpGs) chr1:113498366-113499312
proton-linked 
monocarboxylate transporter 
across the plasma membrane
SLC16A5 hypomethylation TSS200 (3 CpGs) and TSS1500 (1 CpG)
N-shore (1 CpG) 
and island 
(3 CpGs)
chr17:73083866-
73084495
protein localized to the 
cell membrane; acts as a 
proton-linked transporter of 
bumetanide
SP5 hypomethylation gene body (4 CpGs) and 3' UTR (1 CpG)
island (4 CpGs) 
and S-shore 
(1 CpG)
chr2:171569877-
171573904
binds to GC boxes promoter 
elements; probable regulation 
of Wnt-mediated beta catenin 
signaling and target gene 
transcription
TINAGL1 hypomethylation TSS200 (1 CpG) and 5' UTR (2 CpGs) open sea (3 CpGs) N/A
similar to glycoprotein that is 
recognized by antibodies in 
some types of immune-related 
tubulointerstitial nephritis
TNFRSF19 hypomethylation TSS200 (1 CpG) and TSS1500 (2 CpGs)
N-shore (1 CpG) 
and open sea 
(2 CpGs)
chr13:24152899-
24154140
member of the TNF-
receptor superfamily, highly 
expressed during embryonic 
development, and capable 
of inducing apoptosis by 
a caspase-independent 
mechanism
TSPAN9 hypo/hypermethylation
hypomethylated in 
5' UTR (4 CpGs), 
hypermethylated in gene 
body (4 CpGs)
hypomethylated in 
island (4 CpGs), 
hypermethylated in 
open sea (4 CpGs)
chr12:3308812-
3310270
mediates signal transduction 
events in the regulation of 
cell development, activation, 
growth and motility
ZBTB38 hypomethylation 5' UTR (4 CpGs) open sea (4 CpGs) N/A
zinc finger transcriptional 
activator that binds methylated 
DNA; in mouse, inhibition 
of this protein has been 
associated with apoptosis in 
some cell types
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dependent transcription (31 genes). Hypermethylated 
CpG sites were mapped in genes related to organic acid 
transport (14 genes), including fatty acid transport; acyl-
CoA metabolic processes (8 genes); response to hormone 
stimulus (28 genes); response to nutrient levels (17 genes); 
and liver development (8 genes).
Several of the enriched pathways as well as 
the detected relevant biological processes (liver cell 
differentiation and stem cell maintenance) might be 
related to liver development; therefore, we compared 
the differentially methylated CpG sites detected in 
hepatoblastomas with the 28,447 CpG sites found to 
undergo methylation changes during liver development 
[29]. There were 434 differentially methylated CpG 
sites associated to 295 genes, this set was found to 
be significantly enriched during liver development 
(p<0.0001). Among these 434 CpG sites, 142 (17%) were 
hypomethylated and 292 (50%) were hypermethylated, 
with similar patterns of hypomethylation or 
hypermethylation in both hepatoblastomas and fetal livers 
compared with adult livers. Functional annotation of the 
295 genes revealed enrichment in Metabolic, Cancer, 
Insulin, MAPK and Wnt signaling pathways, as well 
as Regulation of the actin cytoskeleton and Adherents 
junction. Three additional pathways, compared to the 
whole set of genes, stood out in relevance, namely citrate 
cycle, tight junction and endocytosis.
Therefore, we sought to verify the performance 
of the global methylation profile in hepatoblastomas 
in relation to the methylomes of fetal and adult liver 
samples using this same study [29] as independent groups 
of liver samples. Beta-values were averaged across 
samples (hepatoblastomas, fetal or adult livers) and 
plotted using the notch boxplot method. This method, 
although not a formal test, infers that if the notches of 
two boxplots do not overlap, then there is strong evidence 
(95% confidence) that their medians differ. The results 
revealed that hepatoblastomas display a significant global 
hypomethylation pattern when compared with both fetal 
and adult differentiated livers (Figure 2).
Upon unsupervised hierarchical clustering of our 
set of 1,359 DMSs, two clusters were formed: cluster 1, 
containing all differentiated liver samples, including those 
from our study except for one sample, which is a paired non-
tumoral sample of a congenital hepatoblastoma (HB33) that 
grouped with tumors; and cluster 2, which further separated 
in two branches, one containing all hepatoblastoma samples 
with exception for HB17, which grouped with all fetal liver 
samples in the other branch (Figure 3).
Furthermore, we performed an in silico gene 
expression analysis of the 765 genes associated with 
the 1,359 differentially methylated CpGs using two 
studies which contain microarray expression data from 
hepatoblastomas and non-tumoral liver samples [30,31]. 
In the first dataset, there were 717 out of 765 genes in 
common to both studies, and expression levels of these 
genes discriminated all non-tumoral liver samples from 
94% (47 out of 50) of the hepatoblastoma samples 
(Supplementary Figure 2A). Using the second dataset, we 
found that 516 out of 765 genes were common to both 
studies, i.e., 516 genes harboring differentially methylated 
sites that were present in the expression microarray; the 
expression levels exhibited by these common set of genes 
discriminated all non-tumoral liver samples from 88% (22 
out of 25) of the hepatoblastoma samples (Supplementary 
Figure 2B). 
Figure 2: Boxplots of beta-values (25th and 75th percentiles) with notches of all >400,000 CpG sites across the groups 
(hepatoblastomas, and fetal and differentiated livers). The line and the diamond indicate median and mean methylation values, 
respectively, and the methylation levels are displayed in the Y axis. Due to the low standard deviation and the large number of beta-values 
within each group, the notches are not visible. However, the median beta-values of the three groups do not overlap, which is a strong 
evidence (95% confidence) that the medians are significantly different, indicating that hepatoblastomas are hypomethylated when compared 
with both fetal and adult differentiated livers.
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Profile of methylation in CpGs sites related 
to retrotransposon sequences (LINE-1) and 
X-chromosome inactivation
LINE-1 sequences are not hypomethylated in 
hepatoblastomas
To clarify whether the hypomethylation in 
hepatoblastomas extends to repetitive sequences, we used 
pyrosequencing to analyze the methylation status of four 
CpG sites mapped within LINE-1 sequences. Generally, 
the LINE-1 methylation levels were very similar across 
hepatoblastomas and normal differentiated and fetal liver 
samples. However, focusing on the analysis of individual 
CpGs, hepatoblastomas from both sets showed a slightly 
hypomethylated pattern only at the first CpG of the LINE-
1 sequence when compared with the differentiated livers 
(p = 0.03802 for set #1 and p = 0.05174 for set #2; Figure 
4). The copy number alteration profile for all samples 
of hepatoblastoma set #1 has been previously evaluated 
by array-CGH [32]; tumor samples with and without 
chromosomal alterations >100 kb were compared with 
control differentiated livers regarding the methylation 
levels of LINE-1. Significant differences in LINE-1 
methylation levels were found again only for the first 
CpG site (Supplementary Figure 3), which is slightly 
hypomethylated in hepatoblastomas with copy number 
alterations (p = 0.0057; the Kruskall-Wallis test also 
indicated a difference of p = 0.0166 between the groups at 
this CpG).
X-chromosome CpG sites exhibit hypomethylation in 
male hepatoblastomas
Using all the samples from our study, the 
methylation levels of CpG sites mapped to the X 
chromosome were recovered to compare tumor and 
control liver samples using a sex-matched approach. The 
methylation profile of the X chromosome was similar 
in female hepatoblastomas compared with female liver 
controls, but hypomethylation was detected in male 
hepatoblastomas (Supplementary Figure 4).
DISCUSSION
Embryonal tumors are believed to evolve from 
the disruption of normal embryogenesis [33]. We 
hypothesized that methylation changes probably 
contribute to this process, and we analyzed DNA 
methylation in normal liver and hepatoblastoma 
samples. Although these are certainly not homogeneous, 
the methylation data showed minimal variance between 
samples and groups, indicating that the correction we 
made before the comparison was efficient. The paired 
comparison between hepatoblastomas and liver samples 
revealed few differentially methylated sites exhibiting 
low-level differences, although the non-paired analysis 
showed higher differences on top of higher number of 
sites. This second finding may be related to inherent 
differences between tumor samples and non-matched 
controls, reinforcing the contribution of the paired 
comparison. Notably, the smaller DMS set detected in 
the paired group is almost completely included in the 
larger DMS set detected in the non-paired analysis.
Our investigation revealed that hepatoblastomas 
exhibit a global low-level hypomethylation pattern 
compared with both normal fetal and differentiated 
livers. This hypomethylation was generally restricted to 
non-repetitive DNA, a pattern unusual for most adult 
solid tumors which exhibit a major hypermethylation 
at promoters and hypomethylation in repetitive 
sequences, mainly LINE-1 [34, 35]. However, similar 
global hypomethylation patterns have recently been 
reported for hepatocellular carcinoma [32], embryonal 
tumor medulloblastomas [36] and, lately, in three 
hepatoblastoma samples [26].
Methylome studies in two other embryonal tumors 
(Wilms tumor and neuroblastoma) reported a methylation 
fingerprint in tissue development genes, similar to what 
we observed in hepatoblastomas. Differentially methylated 
regions detected in Wilms tumor showed hypomethylation 
of renal development genes and were enriched for bivalent 
domains in embryonic stem cells [37]. In neuroblastomas, 
changes in methylation occurred in sequences related to 
functional chromatin domains of development and cancer-
related genes [38].
Recently, a genome-wide methylation analysis 
on hepatoblastomas disclosed four novel tumor 
suppressor genes potentially related to progression in 
hepatoblastoma, with the increase of methylation levels 
in more than four genes being associated with poorer 
prognosis [27].
Functional enrichment analysis of the genes affected 
by abnormal methylation have highlighted the Wnt 
signaling pathway, typically altered in hepatoblastomas 
mainly through a high frequency of CTNNB1 activating 
mutations [10, 39]. Here, we found evidence that 
methylation changes in the genome also interfere with 
Wnt signaling. Moreover, genes impacted by DMSs were 
related to pathways that have been associated with cancer, 
energy and drug metabolism. Glycolysis/gluconeogenesis 
(GNG) are metabolic pathways reciprocally regulated 
in the liver that result in the generation of energy. 
Interestingly, restoration of gluconeogenesis through 
the inhibition of mTOR appears to improve therapeutic 
efficacy against hepatocarcinomas [40]. In addition, 
pathways in cancer, endocytosis and adherens junction 
were cellular signaling pathways in common previously 
reported to be deregulated in hepatoblastomas at 
methylation levels [26]. Regarding the biological 
processes likely to be impaired by methylation changes, 
we identified involvement of genes that maintain the 
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Figure 3: Methylation pattern of combined sample sets from this study (hepatoblastoma and control livers) and 
Bonder et al, 2014 (fetal and adult liver samples). Heatmap from a non-supervised hierarchical clustering based on the methylation 
levels of the common set of 1,359 DMSs identified in this study. One non-tumoral liver sample matched to a hepatoblastoma HB33), and 
one hepatoblastoma sample (HB17) grouped with fetal liver samples (both are indicated by vertical black lines).
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interface between the environment and the phenotype, 
such as those related to the maintenance of nutrient levels 
and response to hormone stimuli.
To date, it is not clear to what extent the cancer-
related epigenetic alterations detected in this study 
correspond to natural epigenetic variability in human 
livers; we are aware that fully differentiated liver samples 
are not an ideal control for methylation studies of 
embryonal tumors. Therefore, we also compared our data 
to a recently published study that analyzed methylation 
changes occurring during liver differentiation [29]. Even 
with different approaches to determine the DMSs in the 
two studies, we found an overlap in the frequency and 
distribution of hypomethylated and hypermethylated 
CpGs in hepatoblastomas/fetal livers compared with fully 
differentiated adult livers. The function of such shared 
CpG sites delineates a stemness profile for hepatoblastoma 
cells. The respective methylation changes may be related 
to the postulated impairment of liver cell differentiation 
leading to the development of hepatic embryonal tumor. 
It was reported a trend towards hypomethylation in fetal 
compared to adult liver samples in all CpG sites [29]. 
Upon clustering, the set of 1,359 DMSs detected in 
hepatoblastomas clearly showed that tumors and normal 
fetal livers clustered together into one branch, and all 
adult liver tissues into another, a finding that supports the 
hypothesis that hepatoblastomas exhibit a methylation 
pattern resembling the early stages of liver development. 
It is likely that hepatoblastoma cells have become fixed 
in time and space also due to methylation changes, i.e. 
they have lost their ability to differentiate further into adult 
liver cells. Adding to this scenario, hepatoblastomas also 
were reported to display an expression pattern comparable 
to fetal livers [30].
In our analysis, the signaling pathways related to 
liver development that may be disturbed by methylation 
changes in hepatoblastomas were Metabolism, Cancer, 
Insulin, MAPK and Wnt signaling pathways, as well 
as Regulation of the actin cytoskeleton and Adherents 
junction. Recovering publicly available expression 
data from two independent studies, we showed that 
the expression levels of the genes associated with the 
detected differentially methylated CpG sites were able 
to discriminate all non-tumoral livers from the great 
majority of the hepatoblastoma samples [30, 31]. This 
result supports the impact of our methylation findings 
on tumor gene expression as well as reinforces the role 
of the detected pathways in the tumorigenic process of 
Figure 4: Boxplot of beta-values (25th and 75th percentiles) with notches representing LINE methylation levels. The 
line and the cross indicate median and mean methylation values, respectively, and the methylation levels are displayed in the Y axis. A. 
Methylation levels (%) of all four CpGs located at LINE-1 sequences. B. Methylation levels (%) of CpG 1 located at LINE-1 sequences: 
Hypomethylation of hepatoblastomas set#1 was significant (*, <0.05, Student t test) only for the CpG1.
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hepatoblastoma. Altogether, these data suggest that DNA 
methylation has a high impact on the expression profile for 
hepatoblastoma development.
Five of the genes with altered methylation have 
been previously reported as altered in liver carcinogenesis. 
HSD17B13 does not have a known function, but was 
suggested as a biomarker for hepatocellular carcinomas 
[41]. DKK3 is part of the Wnt signaling pathway and 
is overexpressed in hepatoblastomas, regardless of 
tumor histology [42]. MYC is a transcriptional factor 
that contributes to liver tumor maintenance [43]. HAL 
is regulated by glucocorticoids and glucagon, and 
catalyzes the first reaction in histidine metabolism via 
preferentially the Protein Kinase A (PKA) pathway [44]. 
IGF2 is a growth factor frequently overexpressed in 
hepatoblastomas due to loss of imprinting at 11p15 or 
paternal uniparental disomy at 11p15 [21].
We found two striking cases in which we believe 
that exome sequencing would help to further clarify their 
tumorigenesis processes. One hepatoblastoma (HB17) 
grouped with the normal liver samples, displaying 
a similar distribution of methylation levels; one can 
speculate that in this particular tumor, the occurrence 
of driver mutations could have triggered the malignant 
transformation early during liver cells differentiation. 
Additionally, a non-tumoral liver sample paired with one 
hepatoblastoma exhibited a methylation pattern more 
similar to undifferentiated liver cells, grouping with the 
fetal rather than the differentiated livers, and near tumors 
in the clustering. This sample was derived from one 
congenital tumor, suggesting that the methylation changes 
have been previously established in the non-tumoral liver 
as a consequence of a highly penetrant germline mutation, 
that might be related to the epigenetic machinery.
Three genes identified in our hepatoblastoma 
analyses were also listed in the top 20 differentially 
methylated genes during liver development: CRP, NNMT 
(both hypermethylated) and C3P1 (hypomethylated). 
Among them, NNMT stood out as an enzyme 
(nicotinamide N-methyltransferase) that regulates hepatic 
nutrient metabolism [45]. NNMT has also been reported 
to be overexpressed in a variety of human cancers and to 
promote epigenetic remodeling in cancer by consuming 
methyl units from S-adenosyl methionine (SAM), 
resulting in a metabolic sink [46]. Recently, it has been 
shown that NNMT and the metabolic state regulate 
pluripotency in human embryonic stem cells (hESCs) 
through the consumption of SAM in naive cells, making 
it unavailable for histone methylation, which represses 
Wnt and activates the HIF pathway [47]. According to 
authors, their findings support the hypothesis that the 
metabolome regulates the epigenetic landscape of the 
earliest steps in human development. Therefore, we 
speculate that NNMT dysregulation caused by epigenetic 
changes may be a suitable mechanism linked to the origin 
of hepatoblastomas, thus deserving further investigation.
Subsequently, we hypothesized that the remaining 
DMSs detected in hepatoblastomas might be related to 
cell transformation and tumor progression rather than the 
maintenance of an undifferentiated cell state. The disease 
enrichment analyses revealed that ten of these remaining 
genes have previously been found in liver neoplasms: 
THRSP, HEPACAM [48], MACC1 [49], TERT [50], 
NUAK1 [51], NDRG1 [52], RASSF1 [53], PRDM2 [54], 
ALDOB [55] and MT1G [23], with MACC1, NDRG1 and 
RASSF1 already associated with prognosis in liver cancers.
Altogether, we suggest that DNA hypomethylation 
of intergenic sequences that were primarily detected in 
hepatoblastomas, as well as the other methylation changes, 
contributes to the impairment of cell differentiation, which 
seems to be required for tumorigenesis in embryonal 
tumors, as reported for meduloblastoma [36], Wilms 
tumor and neuroblastomas [37, 38]. Alternatively, it may 
represent an inherent aspect of hepatic tumorigenesis 
[56]. Both hypotheses are supported by our findings of 
enrichment for methylation changes occurring in genes 
relevant for liver differentiation.
Cytosine methylation not only contributes to 
tissue-specific gene expression but also is associated 
with the silencing of retrotransposons, genomic 
imprinting and X-chromosome inactivation in mammals. 
Therefore, to complement the methylation profile of 
hepatoblastomas, these aspects were explored. LINE-1 
is a retrotransposon repetitive element that constitutes 
approximately 17% of the human genome. It has been 
reported to be hypomethylated in many adult tumors, 
and its methylation level correlates with clinical/
pathological features [57, 58]. No differences were found 
in LINE-1 methylation of hepatoblastomas compared 
with differentiated livers except for the first LINE-1 
CpG, which showed a minor though significant reduction 
in methylation, similarly to results previously described 
[17]. Additionally, in our data, low-level hypomethylation 
of LINE-1 were associated with the occurrence of copy 
number alterations; when comparing tumors with and 
without copy number alterations, hypomethylation 
of the first CpG of LINE-1 was mainly detected in 
hepatoblastomas harboring chromosomal alterations. 
However, the absence of significant hypomethylation of 
repetitive sequences in hepatoblastomas clearly contrasts 
with most of the solid adult tumors. Therefore, the low-
level global hypomethylation reported here is restricted 
to non-repetitive sequences of the tumors, including 
intergenic sequences. Such a hypomethylation pattern 
raises the possibility that intergenic regulatory elements 
may be affected, as has recently been reported for acute 
lymphoblastic leukemia [59].
No differences were detected between female 
hepatoblastomas and control livers regarding the CpG 
sites located on the X chromosome, suggesting that the 
X-inactivation, which takes place in the multipotent 
cell stage during very early embryonic development, 
Oncotarget97884www.impactjournals.com/oncotarget
was already established when the tumor precursor 
cells were laid down, and preserved. Conversely, male 
hepatoblastomas showed a significant loss of methylation 
at X chromosome CpGs, an observation that needs 
to be clarified, but that are in accordance with the 
hypomethylation trend detected in hepatoblastomas in 
general.
Our results pinpoint that DNA methylation, 
mostly a low-level hypomethylation, is a key epigenetic 
mechanism related to hepatoblastoma tumorigenesis, 
in addition to genetic mutations. It remains to be 
addressed in future studies whether there is an active 
process of demethylation working on hepatoblastoma 
origin, possibly involving TET enzymes and 5hmC, 
or alternatively, whether a passive pathway of 
demethylation occurs via inhibition of DNMTs, a 
possibility previously outlined. Low basal levels of 
DNMT1 in hepatoblastoma cell lines confirmed an 
essential role of DNMT1 depletion in the enhancement 
of cancer stem cell properties [60]. The authors have 
demonstrated that epigenetic reprogramming induced 
by transient DNMT1 inhibition influences both 
malignant properties and the pool of hepatic cancer 
stem cells.
CONCLUSIONS
Our results showed that hepatoblastomas exhibit 
a global low-level hypomethylation pattern in non-
repetitive sequences, and an apparent arrest at early 
stages of liver differentiation. This suggests either that 
embryonal tumors are driven by different oncogenic 
mechanisms, as has been observed in other embryonal 
tumors, or that hypomethylation is a major feature of 
liver carcinogenesis because it has also been reported in 
hepatocellular carcinoma. The pathway analysis of the 
differentially methylated genes revealed an enrichment for 
metabolism, negative regulation of cell differentiation, and 
cancer. Moreover, confirming previous genetic findings, 
the Wnt signaling pathway was highlighted, suggesting 
a non-stochastic mechanism of CpG methylation in 
hepatoblastomas. In addition to the methylation landscape, 
we also provided a list of potential candidate genes for 
hepatoblastomas.
MATERIALS AND METHODS
Human tissue samples
Hepatoblastomas and differentiated non-tumoral 
liver samples were provided by the Biobank of the A. 
C. Camargo Cancer Center (ACCCC) and the Pediatric 
Oncology Institute (GRAACC), which are both cancer 
hospitals in São Paulo, Brazil. The institutional review 
board of each institution independently approved the study, 
and informed consent was obtained from the patients’ legal 
guardians. All procedures followed the guidelines of the 
Declaration of Helsinki. All patients received pre-surgical 
chemotherapy according to SIOPEL (http://www.siopel.
org/) or COG (http://www.childrensoncologygroup.org/) 
protocols. Patients were followed by clinical examination, 
imaging tests and measurement of alpha-fetoprotein for a 
minimum period of 18 months.
Sections from tumor tissue blocks stained 
with hematoxylin and eosin were reviewed by a 
pathologist. Samples were grouped into a training set 
(consisting of 8 cases with paired hepatoblastoma and 
differentiated non-tumoral liver samples; described 
here as Hepatoblastoma set#1) and a validation set (11 
hepatoblastomas and 3 unrelated non-tumoral liver 
samples - one patient with undisclosed age, the other 
two patients were 4 and 13 years old; described here as 
Hepatoblastoma set#2).
Genomic DNA isolation
Samples were macrodissected for enrichment of 
neoplastic (at least 70% of homogeneity) or normal 
tissues, followed by DNA extraction performed at the 
Macromolecule Bank (A. C. Camargo Cancer Center). 
Genomic DNA was extracted using phenol:chloroform. 
NanoDrop (Thermo Fisher Scientific) and Qubit (Thermo 
Fisher Scientific) equipment were used to assess DNA 
purity and quantity, and DNA quality was checked by 
electrophoresis in 0.8% agarose gels.
DNA methylation analysis
Bisulfite conversion of 500 ng of DNA was 
performed using the EZ DNA Methylation kit 
(Zymo Research) according to the manufacturer’s 
recommendations. Bisulfite-converted DNA samples 
were hybridized in the Human Methylation 450 BeadChip 
microarrays (HM450K, Illumina), following the Illumina 
Infinium HD methylation protocol. The HM450K 
platform measures the DNA methylation level of 485,577 
loci distributed across the genome at single-nucleotide 
resolution. Data was submitted to NCBI/GEO and is 
available as GSE78732.
The Illumina iScan SQ scanner (Illumina) was used 
to obtain images of the microarrays. The fluorescence 
signals were interpreted with the GenomeStudio software 
(v.2011.1) with the methylation module v.1.9.0 (Illumina). 
Probes were annotated according to the Illumina 
annotation file using UCSC version hg19 of the human 
reference genome. The methylation levels for each CpG 
probe were provided as beta-values ranging from 0 to 1 
(0 indicating unmethylated CpGs, and 1 indicating fully 
methylated CpGs).
The RnBeads package [61] was applied to the 
dataset. A total of 2,001 unreliable probes were identified 
using Greedycut (p>0.05), and removed. Probes located 
in SNPs (4,713 probes) as well as those that do not 
address CpG methylation levels (non-CpG control 
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probes; n=3,140) were also excluded. The background 
was corrected using the noob method, which is based 
on a normal-exponential convolution using out-of-band 
probes [62]. Signal intensities from type I and II probes 
were normalized using the SWAN method, which adjusts 
intensities based on a quantile approach [63]. Probes 
located on the X and Y chromosomes were excluded 
from downstream analyses, unless otherwise disclosed, 
resulting in a total of 422,324 normalized β-values for 
each of the 29 samples (19 hepatoblastomas and 10 
control livers). The SVA package [64], that estimates and 
removes unwanted sources of variation in -omics data, 
was applied to infer surrogate variables from patient's 
characteristics (age at diagnosis, tumor histology, alpha-
fetoprotein level, treatment protocol, progression and 
overall survival). Principal Component Analyses (PCA) 
showed no association between these variables and the 
groups of comparison regarding methylation levels. 
However, adjustments for technical effects, such as batch, 
were performed using default parameters of RnBeads to 
avoid bias.
Differential methylation analysis
Beta-values were transformed into M-values before 
performing comparison between groups, employing an 
empirical Bayesian framework linear model from limma 
[65]. CpG sites with adjusted p-values (adjP) <0.05 
as defined by Benjamini and Hochberg’s method were 
considered to be differentially methylated. Comparisons 
were performed in two steps: a paired analysis in 8 
cases (Hepatoblastoma set #1), and unpaired analyses 
comparing an independent set of 11 hepatoblastomas 
with 3 unpaired non-tumor differentiated liver samples 
(Hepatoblastoma set #2) plus the same set of 8 non-tumor 
differentiated liver samples used in the first comparison. 
The differentially methylated CpG sites (DMSs) that were 
common to both comparisons (paired and unpaired) were 
used for downstream analyses. Notch box plots were used 
to access the distribution of methylation levels of both 
the DMSs across the autosomal chromosomes, and violin 
plots were used to evaluate the methylation levels in the 
X chromosomes of males and females in both cases and 
controls.
Comparison between wild-type (n=15) and 
CTNNB1-mutated (n=4) tumors were performed using the 
same parameters. We identified a weak correlation between 
age at diagnosis (0.48) and alpha-fetoprotein levels 
(-0.53) with group comparison. Accordingly, adjustment 
for the M-values of each sample were performed before 
differential methylation analyses at CpG site levels.
Functional enrichment analyses (Biological 
Processes from Gene Ontology and cellular signaling 
pathways from KEGG) were performed using WebGestalt 
[62] with the whole genome as the background. Features 
with adjP<0.05 (hypergeometric test with Benjamini–
Hochberg adjustment) comprising at least five genes were 
considered significant.
Hepatoblastomas and liver development
Next, we compared our data to CpGs reported to 
exhibit methylation changes during liver development 
[29]. In the mentioned study, HM450K arrays were 
used to identify methylation changes between 14 fetal 
and 96 adult livers, revealing 28,447 differentially 
methylated CpG sites. These data were compared 
with the detected DMSs from our study, taking into 
consideration whether the sites were hypomethylated 
and hypermethylated. In addition, using Modular 
Single-set Enrichment Test (MSET), we assessed 
the enrichment of our DMSs to the differentially 
methylated CpGs between fetal and adult liver samples 
[29], generating an in silico p-value based on 10,000 
random datasets [66].
Furthermore, to obtain a methylation profile of fetal 
and adult livers, the IDAT files from GEO (GSE61279) 
were downloaded, preprocessed and normalized using 
the same analytical procedure applied to our study. 
There were 420,432 common B-values for both datasets, 
ours and the afore mentioned liver development study. 
Average B-values from fetal and adult livers were 
compared with the average B-values of hepatoblastomas 
sets #1 and #2.
Pearson correlation with complete linkage was 
used for non-supervised hierarchical clustering of 
hepatoblastomas and differentiated and fetal liver 
samples; reliability was assessed by bootstrapping using 
multiExperiment Viewer (MeV) software [67].
Differential gene expression analysis
The 765 genes associated with the 1,359 
differentially methylated CpGs detected in our 
study were searched in two different datasets of 
expression microarrays, one of them downloaded from 
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/
experiments/E-MEXP-1851/), which contains data of 
25 hepatoblastomas and four non-tumoral liver samples 
[30], and the second set recovered from GEO (http://
www.ncbi.nlm.nih.gov/geo/; GSE75271), corresponding 
to expression data from 50 hepatoblastomas and five 
non-tumoral liver samples [31]. Expression levels 
representing the set of genes common to our study were 
used for a non-supervised hierarchical clustering of 
hepatoblastomas and non-tumoral liver samples using 
Pearson correlation with average linkage.
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